Glycolytic ATP Fuels the Plasma Membrane Calcium Pump Critical for Pancreatic Cancer Cell Survival
Overview
Affiliations
Pancreatic cancer is an aggressive cancer with poor prognosis and limited treatment options. Cancer cells rapidly proliferate and are resistant to cell death due, in part, to a shift from mitochondrial metabolism to glycolysis. We hypothesized that this shift is important in regulating cytosolic Ca(2+) ([Ca(2+)]i), as the ATP-dependent plasma membrane Ca(2+) ATPase (PMCA) is critical for maintaining low [Ca(2+)]i and thus cell survival. The present study aimed to determine the relative contribution of mitochondrial versus glycolytic ATP in fuelling the PMCA in human pancreatic cancer cells. We report that glycolytic inhibition induced profound ATP depletion, PMCA inhibition, [Ca(2+)]i overload, and cell death in PANC1 and MIA PaCa-2 cells. Conversely, inhibition of mitochondrial metabolism had no effect, suggesting that glycolytic ATP is critical for [Ca(2+)]i homeostasis and thus survival. Targeting the glycolytic regulation of the PMCA may, therefore, be an effective strategy for selectively killing pancreatic cancer while sparing healthy cells.
Aydemir D, Ozturk K, Arslan F, Calis S, Ulusu N Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(11):9051-9066.
PMID: 38884675 PMC: 11522156. DOI: 10.1007/s00210-024-03193-6.
Driver Mutations of Pancreatic Cancer Affect Ca Signaling and ATP Production.
Stopa K, Lozinski F, Kusiak A, Litewka J, Krzysztofik D, Mosiolek S Function (Oxf). 2023; 4(5):zqad035.
PMID: 37575483 PMC: 10413928. DOI: 10.1093/function/zqad035.
PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models.
Park K, Kim J, Kim S, Kim S, Lim J, Kim M BMC Med. 2023; 21(1):38.
PMID: 36726166 PMC: 9893610. DOI: 10.1186/s12916-023-02727-8.
Okuno K, Xu C, Pascual-Sabater S, Tokunaga M, Takayama T, Han H Biomedicines. 2023; 11(1).
PMID: 36672630 PMC: 9855441. DOI: 10.3390/biomedicines11010119.
The modulation of ion channels in cancer chemo-resistance.
Zhao J, Li M, Xu J, Cheng W Front Oncol. 2022; 12:945896.
PMID: 36033489 PMC: 9399684. DOI: 10.3389/fonc.2022.945896.